Fig 5.

Clinical activity of recombinant human interleukin-15 (rhIL-15) in patient with metastatic malignant melanoma. There were no objective remissions in 18 patients, with best response being stable disease. However, five patients had decreases of 10% to 30% in marker lesions. Two patients, including the one shown (patient No. 16), experienced clearance of lung lesions; lesion 2 at (A) baseline and (B) day 42, and lesion 3 at (C) baseline and (D) day 42. Yellow arrows indicate lung lesions; blue lines indicate area measured.